Our partnership continues to give EnvisionInsurance the decision support to improve health outcomes and clinical care for its members
Portland, ME. (PRWEB) July 19, 2016
RxAnte, LLC, the leading platform for improving medication use and drug therapy outcomes through predictive analytics, announced today that it is continuing its partnership with EnvisionInsurance, a national provider of Medicare Part D plans and a division of EnvisionRxOptions. Through this partnership, RxAnte uses data from large populations of patients to predict the future likelihood of individual patients to adhere to their prescribed medication therapies. Applying these predictions, Envision and RxAnte develop customized interventions and outreach programs for each member, which improves health outcomes and better controls costs for members, the plan and our federal government.
With nearly seven of every ten Medicare beneficiaries having two or more chronic conditions (Center for Disease Control, 2013) and many new, higher-cost specialty medications in market, it is more important than ever for Part D plans to ensure members maintain their prescribed drug therapies—so important that CMS tracks and publicly shares how well individual Part D plans support members through Star scores. RxAnte’s existing Medicare Advantage and Prescription Drug Plan clients have improved medication adherence in key Star Rating therapy areas, and the extension of the RxAnte and Envision relationship continues to build on prior success, which saw medication adherence rates improve faster than the national industry average. Going forward, the partnership looks to further improve on patient health outcomes and Envision’s own Star measures by improving medication adherence and the behaviors of Part D members with high blood pressure, cholesterol and diabetes medications.
“EnvisionInsurance is committed to delivering best-in-class quality programs that improve medication use among our patient populations, which in turn help them lead healthier, happier lives,” said Bill Epling, president of EnvisionInsurance. “Through our partnership with RxAnte, we have seen impressive gains across all three adherence therapy areas, contributing to successful clinical outcomes.”
“Our partnership continues to give EnvisionInsurance the decision support to improve health outcomes and clinical care for its members,” said Josh Benner, Pharm D, president of RxAnte. “We’re looking forward to continuing with Envision and leveraging technology to improve the member pharmacy care experience.”
EnvisionInsurance is a division of EnvisionRxOptions, a health care company with a visibly different approach to managing pharmacy benefits. EnvisionInsurance provides prescription benefits to nearly 400,000 individual and group members nationwide through EnvisionRxPlus, its Medicare-approved prescription drug plan. EnvisionInsurance and EnvisionRxOptions are headquartered in Twinsburg, Ohio. EnvisionRxOptions is a wholly owned subsidiary of Rite Aid. For more information, visit http://www.envisionrxoptions.com.
RxAnte is the leading platform for improving medication use and drug therapy outcomes through predictive analytics and targeted clinical programs. Its innovative analytics platform is transforming how organizations work with healthcare professionals, care management intervention providers, and patients to improve the use of safe and effective prescription medications. Created by subject matter experts in medication adherence, health IT, and advanced analytics, the “RxAnte Platform” is a patent-pending set of solutions that includes predictive and decision analytics, advanced evaluation methods, and an innovative platform for provider engagement. Learn more at http://www.rxante.com or follow us on Twitter.
hmills(at)rxante(dot)com | 571.386.8439
bcreek(at)envisionrx(dot)com | 813-690-8503